Review

oc cells ovcar8 (Procell Inc)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Procell Inc oc cells ovcar8

Overexpression of lncRNA LINC00857 in ovarian cancer cells and tissues. ( A ) Relative expression levels of LINC00857 in OC tissues compared to adjacent normal tissues using qRT-PCR ( n = 50). ( B ) Relative expression levels of LINC00857 in OC cell line <t>OVCAR8</t> compared to normal ovarian epithelial cell line IOSE80 using qRT-PCR ( n = 25). Data were presented as mean ± SD; ** p < 0.01; statistical significance was determined using unpaired Student’s t-test. OC, ovarian cancer.

Oc Cells Ovcar8, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oc cells ovcar8/product/Procell Inc
Average 86 stars, based on 1 article reviews

oc cells ovcar8 - by Bioz Stars, 2026-05

86/100 stars

Images

1) Product Images from "METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway"

Article Title: METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway

Journal: Scientific Reports

doi: 10.1038/s41598-025-24958-w

Figure Legend Snippet: Overexpression of lncRNA LINC00857 in ovarian cancer cells and tissues. ( A ) Relative expression levels of LINC00857 in OC tissues compared to adjacent normal tissues using qRT-PCR ( n = 50). ( B ) Relative expression levels of LINC00857 in OC cell line OVCAR8 compared to normal ovarian epithelial cell line IOSE80 using qRT-PCR ( n = 25). Data were presented as mean ± SD; ** p < 0.01; statistical significance was determined using unpaired Student’s t-test. OC, ovarian cancer.

Techniques Used: Over Expression, Expressing, Quantitative RT-PCR

LINC00857 enhances the invasion, migration, proliferation, and stemness of ovarian cancer cell OVCAR8. ( A ) qRT-PCR analysis of LINC00857 expression levels in OVCAR8 cells transfected with si-NC, si-LINC00857, the vector group, or a LINC00857 overexpression plasmid. ( B ) Cell viability was assessed using CCK-8 assay. ( C ) Cell invasion was evaluated using Transwell assay (scale bar = 50 μm). ( D ) Cell migration was measured using scratch assay (scale bar = 100 μm). ( E ) Representative images of sphere-formation assay showing the sphere-forming capacity of OVCAR8 cells in each group (scale bar = 50 μm). ( F–G ) The protein levels of SOX2, NANOG, and Oct4 in OVCAR8 cells. Data were presented as mean ± SD ( n = 3 ~ 5); ** p < 0.01 vs. si-NC; ## p < 0.01 vs. Vector; statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. CCK-8, Cell Counting Kit-8; SOX2, SRY-box transcription factor 2; NANOG, Nanog homeobox; Oct4, octamer-binding transcription factor 4.

Figure Legend Snippet: LINC00857 enhances the invasion, migration, proliferation, and stemness of ovarian cancer cell OVCAR8. ( A ) qRT-PCR analysis of LINC00857 expression levels in OVCAR8 cells transfected with si-NC, si-LINC00857, the vector group, or a LINC00857 overexpression plasmid. ( B ) Cell viability was assessed using CCK-8 assay. ( C ) Cell invasion was evaluated using Transwell assay (scale bar = 50 μm). ( D ) Cell migration was measured using scratch assay (scale bar = 100 μm). ( E ) Representative images of sphere-formation assay showing the sphere-forming capacity of OVCAR8 cells in each group (scale bar = 50 μm). ( F–G ) The protein levels of SOX2, NANOG, and Oct4 in OVCAR8 cells. Data were presented as mean ± SD ( n = 3 ~ 5); ** p < 0.01 vs. si-NC; ## p < 0.01 vs. Vector; statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. CCK-8, Cell Counting Kit-8; SOX2, SRY-box transcription factor 2; NANOG, Nanog homeobox; Oct4, octamer-binding transcription factor 4.

Techniques Used: Migration, Quantitative RT-PCR, Expressing, Transfection, Plasmid Preparation, Over Expression, CCK-8 Assay, Transwell Assay, Wound Healing Assay, Tube Formation Assay, Cell Counting, Binding Assay

LINC00857 participates in the activation of YAP1. ( A ) Correlation analysis between LINC00857 and YAP1 expression based on TCGA database ( n = 353). ( B ) Immunohistochemistry analysis of YAP1 levels in OC tissues compared to adjacent tissues (scale bar = 20 μm); ** p < 0.01. ( C ) Western blot analysis of YAP1 protein expression levels in IOSE80 and OVCAR8 cells; ** p < 0.01. ( D ) Western blot analysis of YAP1, p-YAP1, LATS1, p-LATS1, and TEAD4 protein levels in OVCAR8 cells across groups. Data were presented as mean ± SD ( n = 3); ** p < 0.01 vs. si-NC; ## p < 0.01 vs. Vector; statistical analysis was performed using unpaired two-tailed Student’s t-test (for two-group comparisons) or one-way ANOVA followed by Tukey’s post hoc test (for multiple comparisons). YAP1, yes-associated protein 1; TCGA, The Cancer Genome Atlas; OC, ovarian cancer; p-YAP1, phosphorylated-YAP1; LATS1, large tumor suppressor 1; p-LATS1, phosphorylated-LATS1; TEAD4, TEA domain transcription factor 4.

Figure Legend Snippet: LINC00857 participates in the activation of YAP1. ( A ) Correlation analysis between LINC00857 and YAP1 expression based on TCGA database ( n = 353). ( B ) Immunohistochemistry analysis of YAP1 levels in OC tissues compared to adjacent tissues (scale bar = 20 μm); ** p < 0.01. ( C ) Western blot analysis of YAP1 protein expression levels in IOSE80 and OVCAR8 cells; ** p < 0.01. ( D ) Western blot analysis of YAP1, p-YAP1, LATS1, p-LATS1, and TEAD4 protein levels in OVCAR8 cells across groups. Data were presented as mean ± SD ( n = 3); ** p < 0.01 vs. si-NC; ## p < 0.01 vs. Vector; statistical analysis was performed using unpaired two-tailed Student’s t-test (for two-group comparisons) or one-way ANOVA followed by Tukey’s post hoc test (for multiple comparisons). YAP1, yes-associated protein 1; TCGA, The Cancer Genome Atlas; OC, ovarian cancer; p-YAP1, phosphorylated-YAP1; LATS1, large tumor suppressor 1; p-LATS1, phosphorylated-LATS1; TEAD4, TEA domain transcription factor 4.

Techniques Used: Activation Assay, Expressing, Immunohistochemistry, Western Blot, Plasmid Preparation, Two Tailed Test

METTL3 highly expresses in ovarian cancer cells and promotes the LINC00857 expression by m6A modification. ( A ) Relative expression levels of METTL3 in OC tissues compared to adjacent normal tissues using qRT-PCR ( n = 50). ( B ) The correlation between LINC00857 and METTL3 expression analyzed by Pearson ( n = 108). ( C ) Relative expression levels of METTL3 in OC cell line OVCAR8 compared to normal ovarian epithelial cell line IOSE80 using qRT-PCR ( n = 25). ( D ) The m6A enrichment levels of LINC00857 in IOSE80 and OVCAR8 cells were measured using the MeRIP-qPCR kit ( n = 25). ( E ) Relative METTL3 mRNA expression levels in OVCAR8 cells transfected with si-METTL3 or si-NC ( n = 5). ( F ) Western blot analysis showing METTL3 protein expression in OVCAR8 cells transfected with si-NC or si-METTL3 ( n = 3). ( G ) Relative mRNA expression of LINC00857 in OVCAR8 cells after METTL3 knockdown (si-METTL3) compared to the si-NC group ( n = 5). ( H ) m6A enrichment levels of LINC00857 in OVCAR8 cells transfected with si-METTL3 or si-NC using MeRIP-qPCR ( n = 5). ( I ) RNA pull-down assay showing the binding interaction between LINC00857 and METTL3 ( n = 5). ( J ) RNA stability assay indicating the relative expression of LINC00857 over time in OVCAR8 cells transfected with si-METTL3 or si-NC ( n = 5). Data were presented as mean ± SD; ** p < 0.01; statistical significance was determined using unpaired Student’s t-test. METTL3, methyltransferase-like 3; OC, ovarian cancer; m6A, N6-methyladenosine.

Figure Legend Snippet: METTL3 highly expresses in ovarian cancer cells and promotes the LINC00857 expression by m6A modification. ( A ) Relative expression levels of METTL3 in OC tissues compared to adjacent normal tissues using qRT-PCR ( n = 50). ( B ) The correlation between LINC00857 and METTL3 expression analyzed by Pearson ( n = 108). ( C ) Relative expression levels of METTL3 in OC cell line OVCAR8 compared to normal ovarian epithelial cell line IOSE80 using qRT-PCR ( n = 25). ( D ) The m6A enrichment levels of LINC00857 in IOSE80 and OVCAR8 cells were measured using the MeRIP-qPCR kit ( n = 25). ( E ) Relative METTL3 mRNA expression levels in OVCAR8 cells transfected with si-METTL3 or si-NC ( n = 5). ( F ) Western blot analysis showing METTL3 protein expression in OVCAR8 cells transfected with si-NC or si-METTL3 ( n = 3). ( G ) Relative mRNA expression of LINC00857 in OVCAR8 cells after METTL3 knockdown (si-METTL3) compared to the si-NC group ( n = 5). ( H ) m6A enrichment levels of LINC00857 in OVCAR8 cells transfected with si-METTL3 or si-NC using MeRIP-qPCR ( n = 5). ( I ) RNA pull-down assay showing the binding interaction between LINC00857 and METTL3 ( n = 5). ( J ) RNA stability assay indicating the relative expression of LINC00857 over time in OVCAR8 cells transfected with si-METTL3 or si-NC ( n = 5). Data were presented as mean ± SD; ** p < 0.01; statistical significance was determined using unpaired Student’s t-test. METTL3, methyltransferase-like 3; OC, ovarian cancer; m6A, N6-methyladenosine.

Techniques Used: Expressing, Modification, Quantitative RT-PCR, Transfection, Western Blot, Knockdown, Pull Down Assay, Binding Assay, Stability Assay

LINC00857 reverses the migration, invasion, proliferation, and stemness of OVCAR8 cells inhibited by METTL3 down-regulation. ( A ) Cell viability of OVCAR8 cells was assessed using CCK-8 assay. ( B ) Cell invasion was evaluated using Transwell assay (scale bar = 50 μm). ( C ) Cell migration was measured using scratch assay (scale bar = 100 μm). ( D ) Representative images of sphere-formation assays showing the sphere-forming capability of OVCAR8 cells in each group (scale bar = 50 μm). ( E–F ) Western blot analysis showing the protein levels of SOX2, Oct4, and NANOG in OVCAR8 cells. Data were presented as mean ± SD ( n = 3 ~ 5); ** p < 0.01 vs. NC; ## p < 0.01 vs. si-METTL3; statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. METTL3, methyltransferase-like 3; CCK-8, Cell Counting Kit-8; SOX2, SRY-box transcription factor 2; NANOG, Nanog homeobox; Oct4, octamer-binding transcription factor 4.

Figure Legend Snippet: LINC00857 reverses the migration, invasion, proliferation, and stemness of OVCAR8 cells inhibited by METTL3 down-regulation. ( A ) Cell viability of OVCAR8 cells was assessed using CCK-8 assay. ( B ) Cell invasion was evaluated using Transwell assay (scale bar = 50 μm). ( C ) Cell migration was measured using scratch assay (scale bar = 100 μm). ( D ) Representative images of sphere-formation assays showing the sphere-forming capability of OVCAR8 cells in each group (scale bar = 50 μm). ( E–F ) Western blot analysis showing the protein levels of SOX2, Oct4, and NANOG in OVCAR8 cells. Data were presented as mean ± SD ( n = 3 ~ 5); ** p < 0.01 vs. NC; ## p < 0.01 vs. si-METTL3; statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. METTL3, methyltransferase-like 3; CCK-8, Cell Counting Kit-8; SOX2, SRY-box transcription factor 2; NANOG, Nanog homeobox; Oct4, octamer-binding transcription factor 4.

Techniques Used: Migration, CCK-8 Assay, Transwell Assay, Wound Healing Assay, Western Blot, Cell Counting, Binding Assay

LINC00857 reverses the effect of down-regulation of METTL3 on YAP1. ( A ) Representative protein bands of YAP1, p-YAP1, LATS1 and TEAD4 in OVCAR8 cells across groups. ( B ) Quantification of protein expression levels normalized to GAPDH. Data were presented as mean ± SD ( n = 3); ** p < 0.01 vs. NC; ## p < 0.01 vs. si-METTL3; statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. METTL3, methyltransferase-like 3; YAP1, yes-associated protein 1; p-YAP1, phosphorylated-YAP1; LATS1, large tumor suppressor 1; TEAD4, TEA domain transcription factor 4.

Figure Legend Snippet: LINC00857 reverses the effect of down-regulation of METTL3 on YAP1. ( A ) Representative protein bands of YAP1, p-YAP1, LATS1 and TEAD4 in OVCAR8 cells across groups. ( B ) Quantification of protein expression levels normalized to GAPDH. Data were presented as mean ± SD ( n = 3); ** p < 0.01 vs. NC; ## p < 0.01 vs. si-METTL3; statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. METTL3, methyltransferase-like 3; YAP1, yes-associated protein 1; p-YAP1, phosphorylated-YAP1; LATS1, large tumor suppressor 1; TEAD4, TEA domain transcription factor 4.

Techniques Used: Expressing

Image Search Results

Journal: Scientific Reports

Article Title: METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway

doi: 10.1038/s41598-025-24958-w

Figure Lengend Snippet: Overexpression of lncRNA LINC00857 in ovarian cancer cells and tissues. ( A ) Relative expression levels of LINC00857 in OC tissues compared to adjacent normal tissues using qRT-PCR ( n = 50). ( B ) Relative expression levels of LINC00857 in OC cell line OVCAR8 compared to normal ovarian epithelial cell line IOSE80 using qRT-PCR ( n = 25). Data were presented as mean ± SD; ** p < 0.01; statistical significance was determined using unpaired Student’s t-test. OC, ovarian cancer.

Article Snippet: OC cells (OVCAR8) were provided by Procell Life Science&Technology Co., Ltd (CL-0178, China).

Techniques: Over Expression, Expressing, Quantitative RT-PCR

Journal: Scientific Reports

Article Title: METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway

doi: 10.1038/s41598-025-24958-w

Figure Lengend Snippet: LINC00857 enhances the invasion, migration, proliferation, and stemness of ovarian cancer cell OVCAR8. ( A ) qRT-PCR analysis of LINC00857 expression levels in OVCAR8 cells transfected with si-NC, si-LINC00857, the vector group, or a LINC00857 overexpression plasmid. ( B ) Cell viability was assessed using CCK-8 assay. ( C ) Cell invasion was evaluated using Transwell assay (scale bar = 50 μm). ( D ) Cell migration was measured using scratch assay (scale bar = 100 μm). ( E ) Representative images of sphere-formation assay showing the sphere-forming capacity of OVCAR8 cells in each group (scale bar = 50 μm). ( F–G ) The protein levels of SOX2, NANOG, and Oct4 in OVCAR8 cells. Data were presented as mean ± SD ( n = 3 ~ 5); ** p < 0.01 vs. si-NC; ## p < 0.01 vs. Vector; statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. CCK-8, Cell Counting Kit-8; SOX2, SRY-box transcription factor 2; NANOG, Nanog homeobox; Oct4, octamer-binding transcription factor 4.

Article Snippet: OC cells (OVCAR8) were provided by Procell Life Science&Technology Co., Ltd (CL-0178, China).

Techniques: Migration, Quantitative RT-PCR, Expressing, Transfection, Plasmid Preparation, Over Expression, CCK-8 Assay, Transwell Assay, Wound Healing Assay, Tube Formation Assay, Cell Counting, Binding Assay

Journal: Scientific Reports

Article Title: METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway

doi: 10.1038/s41598-025-24958-w

Figure Lengend Snippet: LINC00857 participates in the activation of YAP1. ( A ) Correlation analysis between LINC00857 and YAP1 expression based on TCGA database ( n = 353). ( B ) Immunohistochemistry analysis of YAP1 levels in OC tissues compared to adjacent tissues (scale bar = 20 μm); ** p < 0.01. ( C ) Western blot analysis of YAP1 protein expression levels in IOSE80 and OVCAR8 cells; ** p < 0.01. ( D ) Western blot analysis of YAP1, p-YAP1, LATS1, p-LATS1, and TEAD4 protein levels in OVCAR8 cells across groups. Data were presented as mean ± SD ( n = 3); ** p < 0.01 vs. si-NC; ## p < 0.01 vs. Vector; statistical analysis was performed using unpaired two-tailed Student’s t-test (for two-group comparisons) or one-way ANOVA followed by Tukey’s post hoc test (for multiple comparisons). YAP1, yes-associated protein 1; TCGA, The Cancer Genome Atlas; OC, ovarian cancer; p-YAP1, phosphorylated-YAP1; LATS1, large tumor suppressor 1; p-LATS1, phosphorylated-LATS1; TEAD4, TEA domain transcription factor 4.

Article Snippet: OC cells (OVCAR8) were provided by Procell Life Science&Technology Co., Ltd (CL-0178, China).

Techniques: Activation Assay, Expressing, Immunohistochemistry, Western Blot, Plasmid Preparation, Two Tailed Test

Journal: Scientific Reports

Article Title: METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway

doi: 10.1038/s41598-025-24958-w

Figure Lengend Snippet: METTL3 highly expresses in ovarian cancer cells and promotes the LINC00857 expression by m6A modification. ( A ) Relative expression levels of METTL3 in OC tissues compared to adjacent normal tissues using qRT-PCR ( n = 50). ( B ) The correlation between LINC00857 and METTL3 expression analyzed by Pearson ( n = 108). ( C ) Relative expression levels of METTL3 in OC cell line OVCAR8 compared to normal ovarian epithelial cell line IOSE80 using qRT-PCR ( n = 25). ( D ) The m6A enrichment levels of LINC00857 in IOSE80 and OVCAR8 cells were measured using the MeRIP-qPCR kit ( n = 25). ( E ) Relative METTL3 mRNA expression levels in OVCAR8 cells transfected with si-METTL3 or si-NC ( n = 5). ( F ) Western blot analysis showing METTL3 protein expression in OVCAR8 cells transfected with si-NC or si-METTL3 ( n = 3). ( G ) Relative mRNA expression of LINC00857 in OVCAR8 cells after METTL3 knockdown (si-METTL3) compared to the si-NC group ( n = 5). ( H ) m6A enrichment levels of LINC00857 in OVCAR8 cells transfected with si-METTL3 or si-NC using MeRIP-qPCR ( n = 5). ( I ) RNA pull-down assay showing the binding interaction between LINC00857 and METTL3 ( n = 5). ( J ) RNA stability assay indicating the relative expression of LINC00857 over time in OVCAR8 cells transfected with si-METTL3 or si-NC ( n = 5). Data were presented as mean ± SD; ** p < 0.01; statistical significance was determined using unpaired Student’s t-test. METTL3, methyltransferase-like 3; OC, ovarian cancer; m6A, N6-methyladenosine.

Article Snippet: OC cells (OVCAR8) were provided by Procell Life Science&Technology Co., Ltd (CL-0178, China).

Techniques: Expressing, Modification, Quantitative RT-PCR, Transfection, Western Blot, Knockdown, Pull Down Assay, Binding Assay, Stability Assay

Journal: Scientific Reports

Article Title: METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway

doi: 10.1038/s41598-025-24958-w

Figure Lengend Snippet: LINC00857 reverses the migration, invasion, proliferation, and stemness of OVCAR8 cells inhibited by METTL3 down-regulation. ( A ) Cell viability of OVCAR8 cells was assessed using CCK-8 assay. ( B ) Cell invasion was evaluated using Transwell assay (scale bar = 50 μm). ( C ) Cell migration was measured using scratch assay (scale bar = 100 μm). ( D ) Representative images of sphere-formation assays showing the sphere-forming capability of OVCAR8 cells in each group (scale bar = 50 μm). ( E–F ) Western blot analysis showing the protein levels of SOX2, Oct4, and NANOG in OVCAR8 cells. Data were presented as mean ± SD ( n = 3 ~ 5); ** p < 0.01 vs. NC; ## p < 0.01 vs. si-METTL3; statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. METTL3, methyltransferase-like 3; CCK-8, Cell Counting Kit-8; SOX2, SRY-box transcription factor 2; NANOG, Nanog homeobox; Oct4, octamer-binding transcription factor 4.

Article Snippet: OC cells (OVCAR8) were provided by Procell Life Science&Technology Co., Ltd (CL-0178, China).

Techniques: Migration, CCK-8 Assay, Transwell Assay, Wound Healing Assay, Western Blot, Cell Counting, Binding Assay

Journal: Scientific Reports

Article Title: METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway

doi: 10.1038/s41598-025-24958-w

Figure Lengend Snippet: LINC00857 reverses the effect of down-regulation of METTL3 on YAP1. ( A ) Representative protein bands of YAP1, p-YAP1, LATS1 and TEAD4 in OVCAR8 cells across groups. ( B ) Quantification of protein expression levels normalized to GAPDH. Data were presented as mean ± SD ( n = 3); ** p < 0.01 vs. NC; ## p < 0.01 vs. si-METTL3; statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. METTL3, methyltransferase-like 3; YAP1, yes-associated protein 1; p-YAP1, phosphorylated-YAP1; LATS1, large tumor suppressor 1; TEAD4, TEA domain transcription factor 4.

Article Snippet: OC cells (OVCAR8) were provided by Procell Life Science&Technology Co., Ltd (CL-0178, China).

Techniques: Expressing

Review

Structured Review

Images

1) Product Images from "METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway"

Similar Products

Image Search Results